Safety and Efficacy Study of Electrotransfer of Plasmid AMEP to Treat Advanced or Metastatic Melanoma

This study has been terminated.
(The study has been halted due to the low enrolment rate.)
Sponsor:
Information provided by (Responsible Party):
BioAlliance Pharma SA
ClinicalTrials.gov Identifier:
NCT01045915
First received: January 8, 2010
Last updated: January 7, 2013
Last verified: May 2012

January 8, 2010
January 7, 2013
July 2010
June 2012   (final data collection date for primary outcome measure)
Determination of Dose Limiting Toxicity defined as any grade 4 clinical, biological or any life-threatening ECG event occurring during the 9 weeks following treatment [ Time Frame: 9 weeks ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01045915 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Safety and Efficacy Study of Electrotransfer of Plasmid AMEP to Treat Advanced or Metastatic Melanoma
Safety and Efficacy of Intratumoural Electrotransfer of Plasmid AMEP in Patients Suffering From Advanced or Metastatic Melanoma: an Open Phase 1 Trial

The objective of the present trial is to evaluate the local and general safety of the intratumoural electrotransfer of increasing doses of Plasmid AMEP in patients suffering from advanced or metastatic melanoma and to identify doses that could be effective on cutaneous lesions in man.

In this open, multicentre, dose escalation study, successive cohorts of 3 patients suffering from advanced or metastatic melanoma will be electrotransferred increasing doses of Plasmid AMEP into cutaneous melanoma lesions in 2 divided doses at one week interval.

Interventional
Phase 1
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Melanoma
Biological: naked DNA coding for protein AMEP
2 injections 1 week interval of 4 increasing doses of plasmid with electrotransfer
Other Names:
  • electrotransfer
  • electroporation
Experimental: Plasmid AMEP electrotransfer
Intervention: Biological: naked DNA coding for protein AMEP
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
5
January 2013
June 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Male or non-pregnant, non-breast feeding female;
  2. Aged between 18 and 75 years;
  3. Stage IIIB, stage IIIC or stage IV melanoma with:

    • At least 2 cutaneous or subcutaneous non necrotic accessible tumours;
    • Tumour size of 1 to 1.5 cm diameter;
    • No minimum distance between the 2 selected lesions;
  4. Progressive melanoma not responding to previous treatments or patients refusing other therapies;
  5. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2;
  6. For women of child-bearing age: effective contraception method (oral contraception or intra-uterine device) used for more than 2 months before the 1st administration and to be maintained for 3 months after the last administration of Plasmid AMEP;
  7. Having given a written informed consent.

Exclusion Criteria:

  1. Patients who can benefit from other melanoma treatments including surgery;
  2. Significant cardiac arrhythmias, electronic pacemakers, defibrillators, or any implanted electronic device;
  3. Recent (less than 6 months) acute vascular diseases (stroke, MI…);
  4. Advanced peripheral arterial diseases, venous ulcers, or scleroderma;
  5. History or treatment of seizures within the last 5 years;
  6. Clinically significant abnormality at pre-study full physical examination;
  7. Any clinically significant ECG abnormalities;
  8. Prior systemic therapy or any other antineoplastic treatments within the last 4 weeks, radiotherapy or surgery unrelated to the fields in question are allowed;
  9. Abnormal renal function (creatinine plasma level > ULN);
  10. Abnormal liver function tests (any of the following):

    • PT < 70%, ASAT, ALAT, alkaline phosphatases, GGT and/or total bilirubin > ULN in the absence of liver metastasis;
    • PT < 70%, ASAT, ALAT > 2 ULN, alkaline phosphatases > 1.5 ULN, GGT > 5 ULN and/or total bilirubin > 3 ULN in the case of liver metastases;
  11. Abnormal bone marrow function: haemoglobin < 10g/dL, WBC < 3.109 /L and/or platelet count < 100.103 /L;
  12. Clinically significant abnormality in pre-study laboratory tests;
  13. Evidence of significant active infection (e.g., pneumonia, wound abscess, etc);
  14. Intractable coagulopathy;
  15. Any significant disease, including psychiatric and dermatology diseases that may affect the proper evaluation of efficacy or safety;
  16. Patients who had participated in another clinical trial in the last 30 days prior to enrolment in the present clinical trial;
  17. Patients unwilling or unable to comply with protocol requirements and scheduled visits.

Note: patients with brain metastases, or waiting for other therapies (i.e. isolated limb perfusion) may be included.

Both
18 Years to 75 Years
No
Contact information is only displayed when the study is recruiting subjects
Denmark,   France,   Slovenia
 
NCT01045915
BA2009/15/01, 2009-013042-88
Yes
BioAlliance Pharma SA
BioAlliance Pharma SA
Not Provided
Study Director: ATTALI Pierre, MD BioAlliance Pharma
BioAlliance Pharma SA
May 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP